Influenza vaccine effectiveness for fully and partially vaccinated children 6 months to 8 years old during 2011-2012 and 2012-2013: The importance of two priming doses

Pediatric Infectious Disease Journal

Volumn 35, Issue 3, 2016, Pages 299-308

  Thompson, Mark G ^a   Clippard, Jessie ^a   Petrie, Joshua G ^a   Jackson, Michael L ^b   McLean, Huong Q ^c   Gaglani, Manjusha ^d   Reis, Evelyn C ^e   Flannery, Brendan ^a   Monto, Arnold S ^a   Jackson, Lisa ^b   Belongia, Edward A ^c   Murthy, Kempapura ^d   Zimmerman, Richard K ^e   Thaker, Swathi ^a   Fry, Alicia M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c MARSHFIELD CLINIC   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; FULL VACCINATION; HUMAN; INFANT; INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; OUTPATIENT; PARTIAL VACCINATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGISTER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; VACCINE EFFECTIVENESS; CLASSIFICATION; FEMALE; HISTORY; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SEASON; UNITED STATES; VACCINATION;

CHILD; CHILD, PRESCHOOL; FEMALE; HISTORY, 21ST CENTURY; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; OUTCOME ASSESSMENT (HEALTH CARE); SEASONS; UNITED STATES; VACCINATION;

EID: 84959186785     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001006     Document Type: Article

References (53)

1. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and metaanalysis. Lancet. 2011;378:1917-1930.
2. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379:2151-2161.
3. Jules A, Grijalva CG, Zhu Y, et al. Influenza-related hospitalization and ED visits in children less than 5 years: 2000-2011. Pediatrics. 2015;135: e66-e74.
4. Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza in young children, 2004-2009. Pediatrics. 2013;131:207-216.
5. Poehling KA, Edwards KM, Weinberg GA, et al.; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31-40.
6. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:36-44.
7. Centers for Disease Control. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Recommendations and Reports: Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control. 2013;62:1-43.
8. Bridges CB, Harper SA, Fukuda K, et al.; Advisory Committee on Immunization Practices. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2003;52:1-34; quiz CE1.
9. Harper SA, Fukuda K, Uyeki TM, et al.; Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2004;53:1-40.
10. Bridges CB, Fukuda K, Uyeki TM, et al.; Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2002;51:1-31.
11. Smith NM, Bresee JS, Shay DK, et al; Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR recommendations and reports: morbidity and mortality weekly report recommendations and reports/centers for disease control. MMWR Recomm Rep. 2006;55:1-42.
12. Fiore AE, Shay DK, Broder K, et al.; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57:1-60.
13. Neuzil KM, Englund JA. Influenza vaccine for young children: two doses are better than one. J Pediatr. 2006;149:737-738.
14. Phillips CF, Phillips CA, Hodgkin WE, et al. Killed subunit influenza vaccine in children. Pediatrics. 1973;52:416-419.
15. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccinenaive 5-8-year-old children. J Infect Dis. 2006;194:1032-1039.
16. Walter EB, Rajagopal S, Zhu Y, et al. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine. 2010;28:4376-4383.
17. Englund JA, Walter EB, Fairchok MP, et al. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics. 2005;115:1039-1047.
18. Schmidt-Ott R, Schwarz T, Haase R, et al. Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. Vaccine. 2007;26:32-40.
19. Ng S, Ip DK, Fang VJ, et al. The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children. PloS One. 2013;8:e59077.
20. Bernstein DI, Zahradnik JM, De Angelis CJ, et al. Influenza immunization in children and young adults: clinical reactions and total and IgM antibody responses after immunization with whole-virus or split-product influenza vaccines. Am J Dis Chil (1960). 1982;136:513-517.
21. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014;58:319-327.
22. Eisenberg KW, Szilagyi PG, Fairbrother G, et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics. 2008;122:911-919.
23. Shuler CM, Iwamoto M, Bridges CB, et al. Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004. Pediatrics. 2007;119:e587-95.
24. Ferdinands JM, Olsho LE, Agan AA, et al. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. J Infect Dis. 2014;210:674-683.
25. Treanor JJ, Talbot HK, Ohmit SE, et al.; US Flu-VE Network. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis. 2012;55:951-959.
26. Joshi AY, Iyer VN, St Sauver JL, et al. Effectiveness of inactivated influenza vaccine in children less than 5 years of age over multiple influenza seasons: a case-control study. Vaccine. 2009;27:4457-4461.
27. Fu C, Xu J, Lin J, et al. Concurrent and cross-season protection of inactivated influenza vaccine against A(H1N1)pdm09 illness among young children: 2012-13 case-control evaluation of influenza vaccine effectiveness. Vaccine. 2015;33:2917-2921.
28. Szilagyi PG, Fairbrother G, Griffin MR, et al.; New Vaccine Surveillance Network. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study. Arch Pediatr Adolesc Med. 2008;162:943-951.
29. Katayose M, Hosoya M, Haneda T, et al. The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. Vaccine. 2011;29:1844-1849.
30. Sugaya N, Nerome K, Ishida M, et al. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA. 1994;272:1122-1126.
31. Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1-62.
32. Fiore AE, Shay DK, Haber P, et al.; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP), 2007. MMWR Recomm Rep. 2007;56:1-54.
33. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morbidity Mortality Weekly Report. 2012;61:613-618.
34. Heinonen S, Silvennoinen H, Lehtinen P, et al. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis. 2011;11:23-29.
35. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211:1529-1540.
36. Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morbidity Mortality Weekly Report. 2012;61:414-420.
37. Influenza activity-United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morbidity mortality Weekly Report. 2013;62:473-479.
38. Interim results: state-specific seasonal influenza vaccination coverage - United States, August 2009-January 2010. MMWR Morbidity Mortality Weekly Report. 2010;59:477-484.
39. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage - United States, October 2009-January 2010. MMWR Morbidity Mortality Weekly Report. 2010;59:363-368.
40. Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PloS One. 2014;9:e92153.
41. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31:2165-2168.
42. Foppa IM, Haber M, Ferdinands JM, et al. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013;31:3104-3109.
43. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morbidity mortality Weekly Report. 2011;60:1128-1132.
44. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013;56:1363-1369.
45. Thompson MG, Li DK, Shifflett P, et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis. 2014;58:449-457.
46. Sullivan SG, Kelly H. Stratified estimates of influenza vaccine effectiveness by prior vaccination: caution required. Clin Infect Dis. 2013;57:474-476.
47. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59:1375-1385.
48. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis. 2015;211:1519-1528.
49. Gilca V, De Serres G, Hamelin ME, et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine. 2011;30:35-41.
50. Skowronski DM, Janjua NZ, Sabaiduc S, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: crossseason and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210:126-137.
51. Walter EB, Neuzil KM, Zhu Y, et al. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Pediatrics. 2006;118:e570-e578.
52. Azziz Baumgartner E, Dao CN, Nasreen S, et al. Seasonality, timing, and climate drivers of influenza activity worldwide. J Infect Dis. 2012;206:838-846.
53. De Serres G, Skowronski DM, Wu XW, et al. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Eurosurveillance. 2013;18.